At a Glance
| Property | BPC-157 | TB-500 |
|---|---|---|
| Amino acids | 15 | 4 |
| Parent protein | Gastric protection compound | Thymosin beta-4 |
| Molecular weight | ~1419.5 g/mol | ~888 g/mol |
| Primary mechanism | VEGFR2, GH receptor, NO modulation | G-actin sequestration, cell migration |
| Research focus | Tendon, gut, neurovascular | Cardiac, wound, fibroblast migration |
| Route in research | IP, SC, oral (GI models) | IP, SC |
| Half-life | Short; tissue effects persist | Moderate |
Origin and Structure
BPC-157 derives from a gastric protection protein identified in human gastric juice. Its 15-amino-acid sequence was synthesized and stabilized for research purposes by Sikiric and colleagues at the University of Zagreb, Croatia, beginning in the 1990s. The peptide's small molecular weight and relative gastric acid stability allow oral administration in GI-focused research designs — an unusual characteristic for a research peptide.
TB-500 is a synthetic tetrapeptide (Ac-LKKTETQ) derived from the central actin-binding domain of thymosin beta-4 (Tβ4), a 43-amino-acid protein involved in actin dynamics, cell migration, and tissue remodeling. The full Tβ4 protein is endogenously expressed in platelets, white blood cells, and a range of tissue types. TB-500 captures the biologically active motif responsible for Tβ4's cell migration-promoting properties in a smaller, more synthetically accessible molecule.
Mechanisms
BPC-157: VEGFR2 pathway modulation supports angiogenesis and endothelial tube formation. Growth hormone receptor upregulation in fibroblasts influences downstream anabolic signaling. Nitric oxide system interaction modulates vasodilation and vascular tone. FAK-paxillin pathway involvement in cell survival and migration has emerged in more recent mechanistic studies.
TB-500: G-actin sequestration is the primary characterized mechanism — TB-500 binds monomeric (G) actin, preventing its incorporation into filamentous (F) actin and thereby modulating cytoskeletal dynamics. This actin regulatory role promotes cell migration, particularly in endothelial cells and fibroblasts. Angiogenic pathway involvement operates through distinct mechanisms from BPC-157, potentially involving upregulation of metalloproteinases and actin-dependent signaling cascades.
Research Domain Comparison
Musculoskeletal research: BPC-157 has substantially more published preclinical data in tendon and ligament injury models. Rat Achilles tendon transection, MCL transection, and bone defect studies predominate. TB-500 data in musculoskeletal models is less extensive but includes wound healing and fibroblast migration studies that are mechanistically relevant to connective tissue repair.
Cardiac and vascular research: TB-500 (and its parent protein Tβ4) has a stronger published literature base in cardiac tissue. Myocardial infarction models, cardiac progenitor cell activation, and epicardial cell mobilization studies feature prominently in Tβ4/TB-500 research. BPC-157 cardiac data exists but is less central to its research profile.
Gastrointestinal research: BPC-157 uniquely occupies this space given its gastric protein derivation. GI mucosal integrity, colitis models, esophageal studies, and short bowel research are BPC-157 domains with no TB-500 equivalent.
Neurological research: BPC-157 has a growing neuroprotection literature. TB-500 neurological research is limited.
Combined Research Rationale
Scientists occasionally design studies incorporating both peptides. The mechanistic rationale is that BPC-157 acts primarily through angiogenic and growth factor signaling pathways, while TB-500 acts through cytoskeletal and cell migration pathways. These represent non-overlapping mechanisms that could produce additive effects during tissue remodeling phases requiring both vascular ingrowth (BPC-157 domain) and organized cell migration (TB-500 domain). This complementarity hypothesis drives combined-use research designs, though head-to-head and combination studies are limited in the published literature.
Application Selection Guide for Researchers
Choose BPC-157 when the study design targets: - Tendon, ligament, or bone repair pathways - Gastrointestinal mucosal biology - Nitric oxide and vascular tone mechanisms - Neurotrophin and neuroprotection pathways - Growth hormone receptor expression in connective tissue
Choose TB-500 when the study design targets: - Actin cytoskeletal dynamics and G-actin regulation - Fibroblast and endothelial cell migration assays - Cardiac tissue remodeling and progenitor cell biology - Wound healing with cell migration as a primary endpoint
Consider both when the design targets: - Complex tissue repair requiring both vascularization and organized cellular migration - Comparative mechanism studies examining different regenerative pathways - Multi-pathway studies where mechanistic orthogonality is methodologically desired
Dosing in Published Research
BPC-157 rodent protocols: 10–100 µg/kg body weight, once daily via IP or SC route in most musculoskeletal studies.
TB-500 rodent protocols: Dosing in published studies ranges from 0.5 mg/kg to 2 mg/kg in injury models; cardiac studies have used varying schedules depending on model acuity.
Both figures represent preclinical research dosing only. No peer-reviewed human pharmacokinetic data exists for either compound.
Sourcing in Canada
Both BPC-157 and TB-500 are available from Canadian domestic research suppliers. When sourcing TB-500, confirm that the COA specifies the tetrapeptide sequence Ac-LKKTETQ and molecular weight of approximately 888 g/mol — not the full thymosin beta-4 protein (5562 g/mol). Mislabeling between the fragment and the full protein has been documented in lower-quality research chemical markets.
Third-party HPLC purity documentation (≥98%) and mass spectrometry confirmation are equally important for both compounds — see how to read a Certificate of Analysis.
Frequently Asked Questions
What is the main difference between TB-500 and BPC-157? BPC-157 is a 15-amino-acid peptide derived from a gastric protection protein, acting mainly through VEGFR2, growth hormone receptor, and nitric oxide modulation. TB-500 is a 4-amino-acid fragment of thymosin beta-4 that works through G-actin sequestration and cell migration. They come from different parent proteins and use non-overlapping mechanisms.
Can BPC-157 and TB-500 be studied together? Yes. Some study designs incorporate both because their mechanisms are non-overlapping — BPC-157 acts through angiogenic and growth factor signaling, while TB-500 acts through cytoskeletal and cell migration pathways. This mechanistic orthogonality could produce additive effects in tissue remodeling, though combination studies in the published literature remain limited.
How do I verify I received TB-500 and not the full thymosin beta-4 protein? Confirm the COA specifies the tetrapeptide sequence Ac-LKKTETQ and a molecular weight of approximately 888 g/mol — not the full thymosin beta-4 protein at 5562 g/mol. Mislabeling between the fragment and the full protein has been documented in lower-quality research chemical markets, so mass-spec confirmation matters.
Which compound has more musculoskeletal research data? BPC-157 has substantially more published preclinical data in tendon and ligament injury models, including rat Achilles tendon transection, MCL transection, and bone defect studies. TB-500 musculoskeletal data is less extensive but includes wound healing and fibroblast migration studies relevant to connective tissue repair.
Research Disclaimer
Neither BPC-157 nor TB-500 is approved by Health Canada or any regulatory authority for human or veterinary therapeutic use. All applications described are exclusively preclinical research contexts. This content is for informational purposes only.